Subscribe To
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...
November 3, 2023, 8:01 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Why is werewolf therapeutics (howl) stock up 20% today?
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This...
November 3, 2023, 10:26 am
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...
November 3, 2023, 10:00 am
Springworks therapeutics reports third quarter 2023 financial results and recent business highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for Novembe...
November 2, 2023, 10:30 am
Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...
November 1, 2023, 11:30 am
Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting
– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...
November 1, 2023, 10:30 am
Context therapeutics reveals ‘encouraging' preclinical data for ctim-76 tumor treatment
Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6...
October 31, 2023, 10:12 am
Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-car...
October 24, 2023, 12:00 pm
Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progress...
October 22, 2023, 11:00 am
Iovance biotherapeutics: testing shareholders' patience
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on ...
October 22, 2023, 9:12 am
Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference
– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...
October 18, 2023, 8:30 pm
Merck's (mrk) keytruda gets fda nod in sixth nsclc indication
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their ...
October 17, 2023, 12:46 pm
Merck's keytruda gets u.s. fda's nod for expanded use in lung cancer
The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients w...
October 16, 2023, 6:58 pm
Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid ...
October 13, 2023, 4:30 pm
Lantheus: fast-growing radiotherapeutics specialist can benefit from lilly's point biopharma takeover
Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product P...
October 12, 2023, 4:35 pm
Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023
SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immun...
October 9, 2023, 12:10 pm
Artios to present initial phase 1 clinical monotherapy data for atr inhibitor art0380 in advanced solid tumors at the european society of medical oncology congress 2023
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replica...
October 5, 2023, 12:00 pm
Verastem: signs of life for a beaten-down equity
Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main ...
October 4, 2023, 9:00 pm
Beyond cancer™ selected to present proffered posters discussing data from the uno therapy program at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that i...
October 4, 2023, 7:30 am
